Solid tumors are abnormal tissue without a liquid area. Most solid tumors are named for the location or type of cell in which they develop, such as breast cancer, prostate cancer, or skin cancer. While solid tumors can be benign, when malignant they are classified as solid tumor cancer.
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
November 13, 2020 4:00 PM PST | November 14, 2020 8:00 AM SGT
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
With the recent successes of immunotherapies, a fresh breeze of optimism in the fight against cancer has reinvigorated the industry. Perhaps the greatest legacy will be the realization of th...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
DATE: July 16, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow devel...
DATE: June 30, 2020 TIME: 10:00 am PDT, 1:00 pm EDT COVID-19 is a highly pathogenic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have assembled a panel...
November 13, 2020 6:00 PM PST | November 14, 2020 10:00 AM SGT
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
November 13, 2020 4:00 PM PST | November 14, 2020 8:00 AM SGT
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemother...
With the recent successes of immunotherapies, a fresh breeze of optimism in the fight against cancer has reinvigorated the industry. Perhaps the greatest legacy will be the realization of th...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
DATE: July 16, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow devel...
DATE: June 30, 2020 TIME: 10:00 am PDT, 1:00 pm EDT COVID-19 is a highly pathogenic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have assembled a panel...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
